| Unique ID issued by UMIN | UMIN000057744 |
|---|---|
| Receipt number | R000065983 |
| Scientific Title | Effects of consumption of the test food on blood amino acid levels: a randomized, open-label, single-ingestion, crossover comparison study |
| Date of disclosure of the study information | 2026/04/30 |
| Last modified on | 2025/10/24 11:30:34 |
Effects of consumption of the test food on blood amino acid levels: a randomized, open-label, single-ingestion, crossover comparison study
Effects of consumption of the test food on blood amino acid levels: a randomized, open-label, single-ingestion, crossover comparison study
Effects of consumption of the test food on blood amino acid levels: a randomized, open-label, single-ingestion, crossover comparison study
Effects of consumption of the test food on blood amino acid levels
| Japan |
Healthy Japanese
| Not applicable | Adult |
Others
NO
To verify the effects of consumption of the test food on blood amino acid levels
Efficacy
Confirmatory
Pragmatic
Not applicable
1. The incremental area under the curve (IAUC) of total amino acid
1. The time to maximum blood concentration (Tmax) and maximum blood concentration (Cmax) of total amino acids, measured values, and changes from pre-consumption values at each time point
2. The IAUC, Tmax, and Cmax of branched-chain amino acids (BCAA), essential amino acids (EAA), non-essential amino acids (NEAA), amino acid fractions, and Fischer ratio, as well as measured values and changes from pre-consumption values at each time point
Interventional
Cross-over
Randomized
Individual
Open -no one is blinded
Active
Institution is not considered as adjustment factor.
YES
2
Educational,Counseling,Training
| Food |
<Duration>
Single ingestion
<Test food>
Test 1: High protein powder
Test 2: Commercially available milk (Meiji Oishii Gyunyu)
<Administration>
Test 1: Dissolve 20 g of high protein powder in 442 mL of water and consume it within 15 minutes after completing the pre-consumption measurement.
Test 2: Consume 442 mL within 15 minutes after completing the pre-consumption measurement.
*The intervention sequence is Test 1 to Test 2.
*The washout period is one week or more.
<Duration>
Single ingestion
<Test food>
Test 1: Commercially available milk (Meiji Oishii Gyunyu)
Test 2: High protein powder
<Administration>
Test 1: Consume 442 mL within 15 minutes after completing the pre-consumption measurement.
Test 2: Dissolve 20 g of high protein powder in 442 mL of water and consume it within 15 minutes after completing the pre-consumption measurement.
*The intervention sequence is Test 1 to Test 2.
*The washout period is one week or more.
| 20 | years-old | <= |
| 60 | years-old | >= |
Male and Female
1. Japanese
2. Men or women
3. Individuals aged between 20 and 60
4. Healthy individuals
5. Individuals whose body mass index (BMI) is less than 30 kg/m2 at screening
1. Individuals who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, or myocardial infarction
2. Individuals who have a pacemaker or an implantable cardioverter defibrillator (ICD)
3. Individuals who are currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, chronic kidney disease, cerebrovascular disorder, rheumatic disease, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases
4. Individuals who are taking "Foods for Specified Health Uses" or "Foods with Functional Claims"
5. Individuals who are taking or using medications (including herbal medicines) or supplements
6. Individuals who are allergic to medicines or foods related to the test product
7. Individuals whose lifestyles are irregular due to working a late-night shift or others
8. Individuals who have food allergies or food intolerances, particularly lactose intolerance
9. Individuals who have developed abdominal pain or gastrointestinal symptoms due to consuming high-protein foods
10. Individuals who have or are undergoing medical treatment for diseases that influence digestion and absorption of nutrients
11. Individuals who are taking steroids, protease inhibitors, or antipsychotics
12. Individuals who are smokers
13. Individuals who have difficulty consuming the food in the prescribed administration
14. Individuals who are pregnant, lactating, or planning to become pregnant during this study
15. Individuals who have been enrolled in other clinical studies within the last 28 days before the agreement to participate in this study or plan to participate in another study during this study
16. Individuals who are judged as ineligible to participate in this study by the physician
14
| 1st name | Tsuyoshi |
| Middle name | |
| Last name | Takara |
Medical Corporation Seishinkai, Takara Clinic
Director
141-0022
9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan
03-5793-3623
t-takara@takara-clinic.com
| 1st name | Naoko |
| Middle name | |
| Last name | Suzuki |
ORTHOMEDICO Inc.
R&D Department
112-0002
2F Sumitomo Fudosan Korakuen Bldg., 1-4-1, Koishikawa, Bunkyo-ku, Tokyo, Japan
03-3818-0610
nao@orthomedico.jp
PlasMEDi Inc.
PlasMEDi Inc.
Profit organization
The ethical committee of the Takara Clinic, Medical Corporation Seishinkai
9F Taisei Bldg., 2-3-2, Higashi-gotanda, Shinagawa-ku, Tokyo, Japan
03-5793-3623
IRB@takara-clinic.com
NO
医療法人社団盛心会 タカラクリニック (東京都)
Medical Corporation Seishinkai, Takara Clinic (Tokyo, Japan)
南町医院 (東京都)
Nerima Medical Association, Minami-machi Clinic (Tokyo, Japan)
| 2026 | Year | 04 | Month | 30 | Day |
Unpublished
16
Completed
| 2025 | Year | 04 | Month | 09 | Day |
| 2025 | Year | 04 | Month | 09 | Day |
| 2025 | Year | 04 | Month | 30 | Day |
| 2025 | Year | 06 | Month | 25 | Day |
| 2025 | Year | 04 | Month | 30 | Day |
| 2025 | Year | 10 | Month | 24 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000065983